The AGPAT2 gene helps the body make and store fat in the right places and supports normal energy balance. If it does not work properly, a person may have very little body fat under the skin from birth, along with a very lean, muscular appearance and later problems such as insulin resistance, high triglycerides, fatty liver, and diabetes. Pathogenic variants in the AGPAT2 gene are a known cause of congenital generalized lipodystrophy type 1, a rare inherited condition.
What is a gene?
Within DNA, a gene is a stretch that carries instructions your cells use to make molecules or regulate processes in the body. Some genes hold the directions for producing proteins, the working parts of cells. Others mainly guide when certain processes occur, where they occur, and how strongly they operate. Taken together, genes affect how the body develops and functions, and they can also shape how you respond to food, stress, or medications. To explore this topic in greater depth, you can find more in the LearnHub.
Overview
AGPAT2Gene function
What if the gene works
The AGPAT2 gene helps fat cells make and store fats that your body uses for energy. It also supports the building of cell membranes, especially in fat tissue.
Risk
What if the gene does not work
Pathogenic variants in the AGPAT2 gene usually cause congenital generalized lipodystrophy, with little body fat from birth, insulin resistance, high triglycerides, and fatty liver. Milder or more severe variants can affect how early features appear and how severe they are.
Treatment
What does that mean for your treatment
A pathogenic variant in the AGPAT2 gene can help guide management used for congenital generalized lipodystrophy, including close treatment of diabetes and very high triglycerides. Metreleptin is an established option for many people with generalized lipodystrophy and can improve blood sugar and triglyceride levels.
Conditions associated with AGPAT2
Gene function
What if the gene works
Your body uses the AGPAT2 gene to help make and handle fats, especially in fat cells. Its protein turns small fat molecules into forms your cells can build on for energy storage and cell membranes. Understanding how the AGPAT2 gene works can make it easier to see how fat tissue supports everyday metabolism.
Inside cells, the AGPAT2 gene helps convert one small fat molecule into phosphatidic acid (a fat-like building block). This step supports the normal making of triglycerides, the main form of stored fat, and other fats used throughout the body.
By supplying these building blocks, the AGPAT2 gene helps fat cells package triglycerides into a usable energy reserve. This is a central part of how the AGPAT2 gene helps fat cells work between meals and during activity.
Some of the fats made through AGPAT2 are used to build cell membranes, the thin layer around each cell. Strong, flexible membranes help cells keep their shape and move substances in and out in a controlled way.
In fat tissue, the AGPAT2 gene supports the normal development and day to day work of fat cells. Mature fat cells can store fuel in an organized way and take part in the body's usual metabolic balance.
What is a variant?
A genetic variant is a small difference in the DNA sequence within a gene. These differences are common and are part of normal human diversity, such as variation in appearance, metabolism, or how the body responds to environmental influences. Many variants do not have any noticeable effect and simply represent natural genetic variation. In some cases, though, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the AGPAT2 gene often make the enzyme unstable, shorten it, or reduce its activity, so cells produce too little phosphatidic acid, a fat building block. Milder variants may leave some activity, while more severe variants can stop the protein being made or lead to the protein being broken down in the cell. This pattern shows how AGPAT2 gene variants affect protein function and may help explain why congenital generalized lipodystrophy type 1 can vary in timing and severity.
How variants are linked to conditions
Pathogenic variants in the AGPAT2 gene cause congenital generalized lipodystrophy type 1, a rare inherited condition that often becomes clear in infancy or childhood. Many people have very little body fat under the skin and may develop insulin resistance, diabetes, high triglycerides, fatty liver disease, or enlargement of the liver and heart. This AGPAT2 gene congenital generalized lipodystrophy type 1 association is the main well-established condition link for this gene.
A variant is not necessarily a diagnosis
Variants in genes are a routine part of human biology and are widely seen across the population. Most do not directly affect health and instead reflect normal human diversity. For many genes, having a variant associated with a condition points to a possible link, not a certain diagnosis, particularly when several genes and environmental influences also play a role. In other situations, though, one well understood variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For AGPAT2, risk is mainly shaped by inheritance: a child is affected when they inherit a harmful AGPAT2 change from both parents, so family history and parents being carriers matter most. Once those gene changes are present, lifestyle does not meaningfully change the chance of having this condition, though good medical care can help watch for and manage complications.
Inheritance of AGPAT2 variants
AGPAT2-related conditions are inherited in an autosomal recessive pattern. That means a child usually inherits one AGPAT2 variant from each parent, and the parents are often healthy carriers. When both parents carry a variant in the AGPAT2 gene, each pregnancy has a 25% chance of the child inheriting both variants and having the condition, a 50% chance of being a carrier, and a 25% chance of inheriting neither variant. This is the key pattern doctors mean when explaining how AGPAT2 variants are inherited in families.
What does my AGPAT2 result mean for my family?
AGPAT2-related lipodystrophy usually runs in families in a recessive pattern, so parents are often healthy carriers and brothers or sisters may also be affected or be carriers. Close relatives may want to learn whether the same gene change is present, especially if there is a family history of very low body fat from birth, insulin resistance, or high triglycerides. For future children, the chance depends on whether both parents carry an AGPAT2 change.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the AGPAT2 gene, clinicians use AGPAT2 genetic testing on a blood or saliva sample. The lab reads the gene’s DNA code and checks for changes linked to inherited lipodystrophy. Results may show a disease causing variant, a benign variant, or an uncertain finding.
When should I consider getting a genetic test?
Consider AGPAT2 testing if a baby or child has very little body fat from early life along with fast growth, an enlarged liver, high triglycerides, or early diabetes. It can also make sense when this pattern runs in the family, especially if related parents have affected children. A result can help confirm congenital generalized lipodystrophy.
A genetic result is only one part of your health story
A genetic result can provide useful insight, but what it reveals varies by the condition and by the type of variant. Over time, many factors, including lifestyle, environment, age, and medical history, affect how the body functions. In some conditions, especially those shaped by many genes, genetic information provides context rather than certainty and is most useful when viewed with other parts of care. In other situations, a genetic result can offer a clear answer. In areas like medication response, genetic results may help put a person’s experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in DNA can change how the body breaks down a drug, moves it through the body, or responds to it where it acts, so the same treatment may work differently from one person to another. This is common and can influence how well a medicine works or how sensitive someone is to side effects.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences can affect a person’s response to medications. It focuses on links between genes and drugs to help explain why the same treatment may work differently from one person to another. For many medicines, genes influence how strongly a drug works or how the body processes it. This information can support treatment decisions that are better informed and more individualized. To explore this topic further, you can learn more in the LearnHub.
Drugs influenced by the AGPAT2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choice or dose. If you have questions about side effects, starting a new medicine, or how treatment fits with your health history, talk with your doctor or pharmacist.
History
Throughout history, people have described striking patterns of near-total lack of body fat in some families, long before the cause was known. In the 20th century, these observations were brought together under what is now called congenital generalized lipodystrophy, based on reports from physicians including Waldemar Berardinelli and Martin Seip. A major step came in 2002, when researchers identified variants in the AGPAT2 gene as a cause of one form of this condition. From these first observations, research expanded steadily, helping doctors separate different genetic types of generalized lipodystrophy. This discovery gave families a clearer genetic explanation and shaped modern diagnosis and classification.